Subject
Cellular and Molecular Neuroscience,Endocrinology,Physiology,Biochemistry
Reference198 articles.
1. Abdelmalek, M., Choi, J., Kim, Y., Seo, K., Hompesch, M., and Baek, S. (2021). HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multicenter, randomized, placebo-controlled trial. Poster Presentation.
2. The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice;Ahrén;Peptides,2021
3. Glucagon control on food intake and energy balance;Al-Massadi;Int. J. Mol. Sci.,2019
4. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose-ranging study;Alba;Clin. Obes.,2021
5. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes;Ali;Am. J. Physiol. -Endocrinol. Metab.,2009
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献